Evidence map›Paper›PMID 42057751›Full record

ArticleJournal of cachexia, sarcopenia and muscle2026

Muscle Health and Prognosis in Patients With Cancer: New Insights.

Emanuele Cereda, Amanda Casirati, Maria Cristina Gonzalez, Nilian Carla Souza, Carla M Prado, Katherine L Ford, Silvia Fernandes Mauricio, Maria Isabel Toulson Davisson Correia, Paolo Pedrazzoli, Riccardo Caccialanza

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Emanuele CeredaClinical Nutrition and Dietetics Unit, Fondazione IRCCS San Matteo, Pavia, Italy.ORCID 0000-0002-0747-1951
Amanda CasiratiClinical Nutrition and Dietetics Unit, Fondazione IRCCS San Matteo, Pavia, Italy.ORCID 0000-0002-6005-5068
Maria Cristina GonzalezPostgraduate Program in Nutrition and Food, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil.ORCID 0000-0002-3901-8182
Nilian Carla SouzaBrazilian National Cancer Institute, Rio de Janeiro, Brazil.ORCID 0000-0003-1396-3386
Carla M PradoDepartment of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-3609-5641
Katherine L FordDepartment of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-8620-9360
Silvia Fernandes MauricioDepartment of Clinical and Social Nutrition, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.ORCID 0000-0003-0909-9177
Maria Isabel Toulson Davisson CorreiaDepartment of Surgery, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-3503-4302
Paolo PedrazzoliMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo and Department of Internal Medicine, University of Pavia, Pavia, Italy.ORCID 0000-0002-9419-7160
Riccardo CaccialanzaClinical Nutrition and Dietetics Unit, Fondazione IRCCS San Matteo, Pavia, Italy.ORCID 0000-0002-9379-3569

Funding

AbbottFondazione IRCCS Policlinico San Matteo
6 · The paper itself

Abstract

backgroundReduced muscle mass and impaired composition have each been independently associated with worse outcomes in patients with cancer. However, emerging evidence suggests that reduced muscle strength-namely, dynapenia-may be particularly important for prognostication, as it is easier to assess in clinical practice compared to muscle mass. Importantly, muscle mass and composition-as assessed with computed tomography images-may not fully capture key physiological changes and/or reflect whole-body alterations, particularly in patients who remain within the normal range. We investigated the predictive power for mortality of low muscle mass and impaired composition, weight loss (WL) and low strength, as well as their combination, in a cohort of patients with cancer.

methodsBaseline data on muscle mass and radiodensity (Hounsfield units [HU]) at the L3 level-assessed using computed tomography-along with 6-month unintentional WL (relevant if ≥ 10% of usual body weight) and muscle strength by handgrip were pooled for 477 patients with cancer (59.1% male, mean age 61.2 ± 12.8 years) from studies conducted in Brazil, Canada and Italy. Patients were categorized by sex and body mass index-specific cutoffs for low skeletal muscle mass index, low skeletal muscle radiodensity, WL ≥ 10% and low handgrip strength. Patients were followed for at least 12 months until death or censoring.

resultsDuring a median follow-up of 43 months (IQR: 28-83), 188 patients died. Kaplan-Meier analysis showed no survival differences for low skeletal muscle index or low radiodensity, regardless of handgrip strength. Only WL ≥ 10% consistently identified patients with poorer prognosis, independently of low handgrip strength. Fully adjusted Cox's regression models showed an independent association only with WL (HR = 1.56 [95% CI: 1.12;2.16]; p = 0.008) and low handgrip strength (HR = 2.07 [95% CI: 1.47;2.92]; p < 0.001), as well as an increased risk for all low handgrip strength/%WL categories. Mortality risk increased across all low handgrip strength/%WL categories. Among the eight risk groups combining low skeletal muscle mass index, WL ≥ 10% and low handgrip strength, only those including WL ≥ 10% and low handgrip strength were significantly associated with higher mortality. Low skeletal muscle mass index contributed to a worse prognosis only when combined with both WL ≥ 10% and low handgrip strength. Similar results were observed when skeletal muscle radiodensity was used in replacement of skeletal muscle mass index.

conclusionsIn patients with cancer, muscle strength and WL were stronger survival predictors than muscle mass and composition, reinforcing their relevancy as easily assessed key markers of muscle health.

Indexed as

Muscle, SkeletalNeoplasmsAgedBody CompositionFemaleHand StrengthHumansMaleMiddle AgedMuscle StrengthPrognosisTomography, X-Ray Computedcancerhandgrip strengthmortalitymuscle massmuscle radiodensitysarcopenia

Identifiers

PMID42057751
PMCPMC13129677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.